title: Therapy of invasive aspergillosis with itraconazole: improvement of therapeutic efficacy by early diagnosis.
abstract: We report on the treatment of invasive aspergillosis with the new triazole antimycotic agent itraconazole. All 11 patients suffered from pulmonary invasive aspergillosis. Two patients also had cerebral aspergillosis; in one of these patients the paranasal sinuses were also invaded. Underlying diseases were acute lymphoblastic leukaemia (n = 3), acute myeloid leukaemia (n = 4); one patient underwent allogeneic bone marrow transplantation before he developed aspergillosis; another was transplanted after successful aspergillosis treatment, liver cirrhosis (n = 1), lung infarction after pulmonary embolism (n = 1), chronic bronchitis after pulmonary tuberculosis (n = 1) and AIDS (n = 1). In five cases initial diagnosis was established by means of mycological methods and clinical signs. In six patients invasive pulmonary aspergillosis was initially diagnosed due to the clinical criteria presented in this paper. Secondary mycological confirmation after onset of therapy was achieved in five out of these six patients. All of the patients initially responded to therapy. One female patient experienced a relapse of aspergillosis and died of cerebral involvement and relapsing leukaemia. Two further patients died due to underlying diseases (pulmonary embolism, relapsing leukaemia). Nine patients (82%) were cured of the mycosis, including the patient with cerebral involvement; two underwent surgical resection of residual pulmonary lesions. Itraconazole is a very effective drug for treatment of invasive aspergillosis. Therapeutic efficacy can be optimized by early diagnosis using clinical criteria and prompt start of treatment.
authors.affiliation: Abteilung Gastroenterologie und Hepatologie, Universität Freiburg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Kreisel
authors.forename: G
authors.initials: G
authors.lastname: Köchling
authors.forename: C
authors.initials: C
authors.lastname: von Schilling
authors.forename: M
authors.initials: M
authors.lastname: Azemar
authors.forename: B
authors.initials: B
authors.lastname: Kurzweil
authors.forename: G
authors.initials: G
authors.lastname: Dölken
authors.forename: A
authors.initials: A
authors.lastname: Lindemann
authors.forename: U
authors.initials: U
authors.lastname: Blum
authors.forename: M
authors.initials: M
authors.lastname: Windfuhr
authors.forename: J
authors.initials: J
authors.lastname: Müller
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy*; D001927:Brain Diseases / Q000188:drug therapy; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole